Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral REOLYSIN + Gemcitabine/Cisplatin in Muscle-Invasive Bladder Cancer
NCT02723838Phase 1Withdrawn
- Sponsor
- Oncolytics Biotech Inc.
- Start
- Feb 2017
- Primary completion
- Sep 2017
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of pelareorep in muscle-invasive bladder cancer (MIBC) (3 cohorts), sponsored by Oncolytics Biotech Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Tumor Viability in Biopsies and 4 more. Planned start Feb 2017; status: withdrawn.
02
Drugs
pelareorep
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT02723838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723838.